{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-229076","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2026-05-18T20:51:59+00:00","discovered_at":"2026-05-18T20:53:00.238760+00:00","generated_at":"2026-05-18T20:53:37.980012+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Wave Life Sciences WVE-006 phase 1b/2a data shows MZ-like phenotype with monthly dosing, FDA feedback expected mid-2026","bullets":["WVE-006 achieved 64.4% wild-type M-AAT (matching protective MZ phenotype) and 70.5% reduction in toxic Z-AAT in 200 mg biweekly cohort.","Monthly 400 mg dosing yielded similar results: 58.7% M-AAT, 67.7% Z-AAT reduction, and 13.6 µM total AAT.","Dynamic AAT production restored during acute phase responses (common cold); CRP and AAT strongly correlated (r=0.73, p<0.001).","WVE-006 well tolerated with no serious AEs or liver toxicities; monthly subcutaneous dosing confirmed feasible.","Wave expects FDA feedback on accelerated approval pathway mid-2026; 600 mg monthly cohort data due H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-229076","json":"https://secwatch.observer/filing/0001193125-26-229076.json","markdown":"https://secwatch.observer/filing/0001193125-26-229076.md","text":"https://secwatch.observer/filing/0001193125-26-229076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526229076/0001193125-26-229076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526229076/d154261d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T20:53:37.980012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}